Sarah Mehuron, MD
Family Medicine · Tampa, FLNPI 1255620084
Payments from drug & device makers
Across 290 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$879
- AstraZeneca$640
- AbbVie$465
- Pfizer$404
- Boehringer Ingelheim$339
- Lilly USA, LLC$322
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,608100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $879 |
| AstraZeneca | 37 | $640 |
| AbbVie(2 entities) | 27 | $465 |
| Pfizer | 23 | $404 |
| Boehringer Ingelheim | 22 | $339 |
| Lilly USA, LLC | 21 | $322 |
| Astellas Pharma US Inc | 13 | $245 |
| Amarin Pharma, Inc. | 13 | $175 |
| GSK | 9 | $166 |
| Amgen | 9 | $144 |
| Dexcom, Inc. | 6 | $118 |
| Corium, LLC | 4 | $92 |
| Abbott | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 5 | $66 |
| Merck | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Antares Pharma, Inc. | 3 | $51 |
| Shield Therapeutics Inc | 2 | $44 |
| Johnson & Johnson | 2 | $38 |
| Edwards Lifesciences | 1 | $31 |
| Nevro Corp. | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $13 |
How this compares
$4,620 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $119,650 |
| TrulicityDulaglutide | 55 | $64,242 |
| EliquisApixaban | 57 | $62,455 |
| JardianceEmpagliflozin | 56 | $58,122 |
| MounjaroTirzepatide | 39 | $48,317 |
| FarxigaDapagliflozin Propanediol | 35 | $34,362 |
| TradjentaLinagliptin | 23 | $31,717 |
| XareltoRivaroxaban | 26 | $27,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,932 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $17,988 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $15,114 |
| EntrestoSacubitril/Valsartan | 15 | $14,756 |
| TrintellixVortioxetine Hydrobromide | 15 | $12,246 |
| Repatha SureclickEvolocumab | 13 | $8,193 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $6,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $879 | $119,650126 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $322 | $112,55994 claims |
| Boehringer IngelheimJardiance, Tradjenta | $339 | $89,83979 claims |
| PfizerEliquis | $404 | $62,45557 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $640 | $56,21074 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $166 | $37,92057 claims |
| Johnson & JohnsonXarelto | $38 | $27,39626 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $66 | $12,24615 claims |
| MerckJanumet | $62 | $6,51911 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $66 | $4,66011 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15 | $3,25312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Tampa
- Lon LynnTampa$9.7M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.